Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
复制标题
使用 (S)-1-(3-羟基-2-膦酰甲氧基丙基)胞嘧啶 (HPMPC) 成功治疗由阿昔洛韦和膦甲酸钠耐药的单纯疱疹病毒引起的进行性皮肤粘膜感染。
DOI：
--
复制
发表时间：
1994
影响因子：
11.8
通讯作者：
E. D. Clercq
中科院分区：
文献类型：
--
作者：
R. Snoeck;G. Andrei;Marie;A. Silverman;A. Hedderman;J. Balzarini;C. Sadzot;G. Tricot;N. Clumeck;E. D. Clercq
本文报告了2例持续性皮肤粘膜感染患者局部应用无环核苷膦酸盐（S）-1-（3-羟基-2-膦酰甲氧基丙基）胞嘧啶（HPMPC）治疗的临床疗效。1例艾滋病患者因单纯疱疹病毒2型（HSV-2）感染而出现会阴病变，对阿昔洛韦无反应，对膦甲酸不耐受。一名骨髓移植受者因感染1型单纯疱疹病毒（HSV-1）而出现口面部病变，而无环鸟苷和膦甲酸治疗均无反应。局部应用HPMPC后，HSV-2病变完全消退。然而，3周后病变复发，随后接受HPMPC治疗后，病变消退。在复发时，发现病毒对患者给予的阿昔洛韦敏感。再次出现对阿昔洛韦耐药的HSV-2;在另一个周期的HPMPC治疗后进行了类似的观察。HSV-1分离株对阿昔洛韦和膦甲酸耐药。局部HPMPC治疗后，病变消退，但1周后，必须开始第二个疗程的局部HPMPC治疗复发性感染。病变再次消退，由于复发病毒对阿昔洛韦敏感，患者成功接受药物治疗。本研究的结果表明，局部HPMPC在治疗免疫功能低下的HSV相关皮肤粘膜感染患者中具有潜在的实用性，这些患者对阿昔洛韦和/或膦甲酸治疗无效。
The acyclic nucleoside phosphonate (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) was used topically for the treatment of persistent mucocutaneous infections in two cases. One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet. A bone marrow transplant recipient developed orofacial lesions due to infection with herpes simplex virus type 1 (HSV-1) that failed to respond to therapy with both acyclovir and foscarnet. After topical application of HPMPC, the HSV-2 lesions completely resolved. However, the lesions recurred 3 weeks later, and, upon subsequent treatment with HPMPC, regressed. On recurrence, the virus was found to be sensitive to acyclovir, which the patient was given. Again HSV-2, which was resistant to acyclovir, emerged; similar observations were made after another cycle of HPMPC therapy. The HSV-1 isolates were resistant to acyclovir and foscarnet. Following local HPMPC treatment, the lesions regressed, but after 1 week, a second course of topical HPMPC therapy had to be instituted for recurrent infection. The lesions again regressed, and as the recurrent virus was sensitive to acyclovir, the patient was successfully treated with the drug. The results of this study point to the potential usefulness of topical HPMPC in the treatment of immunocompromised patients with HSV-related mucocutaneous infections that are refractory to therapy with acyclovir and/or foscarnet.
登录
查看更多内容
影响因子：
39.2
作者：
Stephen L. Sacks;R. J. Wanklin;Donna E. Reece;Karen A. Hicks;Kenneth L. Tyler;Donald M. Coen
通讯作者：
Stephen L. Sacks;R. J. Wanklin;Donna E. Reece;Karen A. Hicks;Kenneth L. Tyler;Donald M. Coen
艾滋病患者体内对阿昔洛韦耐药的单纯疱疹病毒 2 型脑膜脑炎。
DOI：
10.1093/infdis/161.4.711
发表时间：
1990
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Gateley,A;Gander,RM;Johnson,PC;Kit,S;Otsuka,H;Kohl,S
通讯作者：
Kohl,S
影响因子：
7.6
作者：
D. Coen
通讯作者：
D. Coen
影响因子：
158.5
作者：
CRUMPACKER, CS;SCHNIPPER, LE;LEVIN, MJ
通讯作者：
LEVIN, MJ
DOI：
10.1093/infdis/148.6.1077
发表时间：
1983-12
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
J. Wade;C. Mclaren;J. Meyers
通讯作者：
J. Wade;C. Mclaren;J. Meyers